| Basics |
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
|
| IPO Date: |
August 23, 1999 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$66.01M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 3.61%
|
| Avg Daily Range (30 D): |
$0.06 | 3.22%
|
| Avg Daily Range (90 D): |
$0.06 | 3.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.92M |
| Avg Daily Volume (30 D): |
.5M |
| Avg Daily Volume (90 D): |
.69M |
| Trade Size |
| Avg Trade Size (Sh.): |
273 |
| Avg Trade Size (Sh.) (30 D): |
164 |
| Avg Trade Size (Sh.) (90 D): |
175 |
| Institutional Trades |
| Total Inst.Trades: |
3,982 |
| Avg Inst. Trade: |
$1.61M |
| Avg Inst. Trade (30 D): |
$1.65M |
| Avg Inst. Trade (90 D): |
$1.65M |
| Avg Inst. Trade Volume: |
.02M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.59M |
| Avg Closing Trade (30 D): |
$1.65M |
| Avg Closing Trade (90 D): |
$1.65M |
| Avg Closing Volume: |
44.82K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-3.17
|
$-.51
|
|
|
Diluted EPS
|
$-3.17
|
$-.51
|
|
|
Revenue
|
$ .28M
|
$ .07M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -96.48M
|
$ -19.69M
|
$
|
|
Operating Income / Loss
|
$ -105.96M
|
$ -25.05M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 20.31M
|
$ -25.9M
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
| Jan 25, 2024:
12:1
|
| Jun 09, 2014:
4:1
|
| Jun 06, 2014:
4:1
|
| Sep 13, 2004:
4:1
|
|
